earn focu
impact pipelin
maintain equal weight rate share
increas price target
ep vs prior follow review oper result
outlook perform solid believ
share fulli valu current growth remain less optimist
regard prospect aimovig growth sotorasib
success kra tumor differenti t-cell engag
report oper result today
provid updat commerci perform key initi
non-gaap ep ahead consensu estim
revenu vs consensu lower expect
opex guidanc remain unchang product sale
non-gaap ep
increas non-gaap ep estim vs
non-gaap ep estim unchang
focu product perform note differ impact
across product portfolio focu hcp-
administ drug bone franchis affect
oncolog busi specif prolia sale
vs consensu even sale vs
consensu xgeva sale vs
consensu legaci product sale mix enbrel in-
line consensu neulasta in-lin
consensu sale vs consensu
aranesp sale vs consensu epogen
sale vs consensu newer product sale
includ aimovig sale vs consensu repatha
sale vs consensu otezla sale
gener in-lin expect
focu pipelin updat commit initi
clinic trial otezla compani see
broad opportun across varieti set note
limit impact late-stag pipelin
compani continu expect follow data readout phase
data otezla mild-to-moder psoriasi data
phase galactic-hf studi omecamtiv heart failur
phase navig studi result tezepelumab sever
uncontrol asthma late top-lin data
potenti pivot phase studi sotorasib kras-
non-smal cell lung cancer also comment
encourag data long half-lif hle bite led
termin bcma psma gener bite data
hle bite present virtual follow
data bcma psma
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
compani data secur llc estim reuter
price target
arriv price target appli multipl ep estim risk includ
biosimilar threat enbrel slower expect growth newli launch product otezla repatha
aimovig even parsabiv biosimilar disappoint result late stage phase pipelin
product omecamtiv mecarbil tezepelumab sotorasib
expens price-to-earnings basi rel growth view face signific headwind
biosimilar brand competit legaci franchis
larg cap global commercial-stag biotechnolog compani discov develop biolog
small molecul drug specialti physician discoveri pipelin led compani
broaden focu oncolog immune-medi inflammatori diseas renal diseas includ
bone diseas cardiovascular neurolog diseas addit taken lead posit
develop biosimilar compani face near-term biosimilar competit legaci
